Connor, Clark & Lunn Investment Management Ltd. Kinnate Biopharma Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2023 Feb 09, 2024	BUY	$1.07 - $2.5 $26,394 - $61,670	24,668 Added 47.29%	76,836 $182,000
Q3 2023 Nov 13, 2023	BUY	$1.38 - $3.31 $71,991 - $172,676	52,168 New	52,168 $73,000

Others Institutions Holding KNTE

# of Institutions

Shares Held

292K

Call Options Held

Put Options Held

Foresite Capital Opportunity Management V, LLC Larkspur, CA

292K
Shares

$0
10.46% of portfolio
Wipfli Financial Advisors Llc,

109
Shares

$0
0.0% of portfolio

View Full List

About Kinnate Biopharma Inc.

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

More about KNTE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account